A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GLPG3667 in Subjects With Moderate to Severe Plaque Psoriasis
Sponsor: Galapagos NV
Listed as NCT04594928, this PHASE1 trial focuses on Plaque Psoriasis and remains completed. Sponsored by Galapagos NV, it has been updated 9 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2021 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Mar 2021 — Jun 2021 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE1
First recorded
Oct 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Galapagos NV
For direct contact, visit the study record on ClinicalTrials.gov .